Replies to post #705751 on NorthWest Biotherapeutics Inc (NWBO)

[mike00h]

I doubt it. DCVax will require a rewrite of the Standard of Care for all solid cancers. Save your critique for later.

[Chiugray]

MarkoMD, Thanks for your reply. I am not a doctor, so if my logic is wrong, any feedback would be appreciated.

My assumption is:
- today's cancer drugs are typically limited to treating malignant tumors
- most patients with benign tumors are treated with surgery, radiation, and or monitoring (wait and see)
- the reason is, drugs with risk for high toxicity have restrictive labeling for use only in malignant tumors
- much easier for a doctor to off-label a non-toxic vaccine than a toxic drug
- if the patient with a benign tumor is doing surgery to remove it anyway, why not use DCVax-L
- given DCVax-L is non-toxic, generates an immune response, and leaves behind immune memory, there is no downside
- DCVax would be prophylactic

My conclusions:
- Patients would ask for and doctors would strongly consider providing DCVax to patients with benign cancer
- DCVax penetrates the benign tumor therapy market where other cancer drugs have not been able to.